Literature DB >> 9367867

The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation.

M Gana-Weisz1, R Haklai, D Marciano, Y Egozi, G Ben-Baruch, Y Kloog.   

Abstract

Inhibition of Ras-dependent signaling and of oncogenic Ras function by farnesyl transferase inhibitors that block Ras membrane anchorage is limited due to alternative prenylation of Ras. Here we demonstrate that inhibition of the Ras-dependent Raf-1-MAPK (mitogen activated protein kinase) cascade is achieved by S-farnesylthiosalicylic acid (FTS) which affects Ras membrane association but not Ras farnesylation. FTS interferes with the activation of Raf-1 and MAPK and inhibits DNA synthesis in Ras-transformed EJ cells at concentrations similar to those at which it inhibits EJ cell growth (5-25 microM). FTS also inhibits MAPK activity and DNA synthesis stimulated by serum, EGF or thrombin in serum-starved untransformed Rat-1 cells, demonstrating the generality of its effects on Ras-dependent signaling. The effects of FTS on MAPK activity developed relatively rapidly (within 2-6 h) consistent with its rapid effect on Ras membrane anchorage. FTS represents a new class of Ras antagonists that may be useful for the inhibition of various types of oncogenic Ras isoforms independently of their prenylation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9367867     DOI: 10.1006/bbrc.1997.7582

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.

Authors:  D M Beaupre; R Kurzrock
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 2.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

3.  Novel Ras antagonist blocks human melanoma growth.

Authors:  B Jansen; H Schlagbauer-Wadl; H Kahr; E Heere-Ress; B X Mayer; H Eichler; H Pehamberger; M Gana-Weisz; E Ben-David; Y Kloog; K Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

4.  Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).

Authors:  A Katzav; Y Kloog; A D Korczyn; H Niv; D M Karussis; N Wang; R Rabinowitz; M Blank; Y Shoenfeld; J Chapman
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

5.  Vitamin D and S-farnesylthiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation.

Authors:  Rina Neeman; Shirley Abramovitch; Efrat Sharvit; Galit Elad-Sfadia; Roni Haklai; Yoel Kloog; Shimon Reif
Journal:  Dig Dis Sci       Date:  2014-06-19       Impact factor: 3.199

6.  Substrate Stiffness and Stretch Regulate Profibrotic Mechanosignaling in Pulmonary Arterial Adventitial Fibroblasts.

Authors:  Ariel Wang; Shulin Cao; Jennifer C Stowe; Daniela Valdez-Jasso
Journal:  Cells       Date:  2021-04-23       Impact factor: 7.666

7.  Ras Signaling Inhibitors Attenuate Disease in Adjuvant-Induced Arthritis via Targeting Pathogenic Antigen-Specific Th17-Type Cells.

Authors:  Morad Zayoud; Victoria Marcu-Malina; Einav Vax; Jasmine Jacob-Hirsch; Galit Elad-Sfadia; Iris Barshack; Yoel Kloog; Itamar Goldstein
Journal:  Front Immunol       Date:  2017-07-07       Impact factor: 7.561

8.  Increased Apoptosis in the Paraventricular Nucleus Mediated by AT1R/Ras/ERK1/2 Signaling Results in Sympathetic Hyperactivity and Renovascular Hypertension in Rats after Kidney Injury.

Authors:  Hongguo Zhu; Lishan Tan; Yumin Li; Jiawen Li; Minzi Qiu; Lanying Li; Mengbi Zhang; Min Liang; Aiqing Li
Journal:  Front Physiol       Date:  2017-02-02       Impact factor: 4.566

9.  Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib.

Authors:  Raya Faigenbaum; Roni Haklai; Gilad Ben-Baruch; Yoel Kloog
Journal:  Oncotarget       Date:  2013-02

10.  KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.

Authors:  Saveri Bhattacharya; Mark A Socinski; Timothy F Burns
Journal:  Clin Transl Med       Date:  2015-12-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.